Medications for Alcohol Withdrawal and Chronic Alcohol Abuse

Introduction to Alcohol Withdrawal and Chronic Alcohol Abuse Medications

  • Presented by Dr. Lee Rados

  • Focused on practical approaches to managing alcohol withdrawal and treatment of Alcohol Use Disorder (AUD) with pharmacotherapy.

  • Background: Experience in family medicine, now specializing in addiction medicine.

  • Objective: Equip attendees to effectively detox patients and initiate/manage treatment for AUD, both FDA-approved and off-label.

Alcohol Withdrawal Management

Symptoms and Timeline of Alcohol Withdrawal

  • Symptoms typically develop 1 to 3 days after cessation for chronic users:

    • Anxiety

    • Insomnia

    • Nausea

    • Tremors

    • Agitation

    • Autonomic instability (e.g., elevated heart rate, blood pressure changes)

    • Severe symptoms can occur:

      • Fevers

      • Profound confusion

  • Symptoms can persist for weeks in some patients.

  • Serious withdrawal symptoms may occur in 10% of users:

    • Psychotic symptoms, seizures, dysrhythmias, hyperthermia, hypertension.

  • Alcohol withdrawal and benzodiazepine withdrawal can be fatal compared to withdrawal from other substances.

Assessment and Screening

  • CIWA (Clinical Institute Withdrawal Assessment for Alcohol Scale):

    • Most widely used withdrawal assessment tool, especially in inpatient settings, but can be adapted to outpatient settings.

    • Ranges from mild to severe based on symptoms; important in determining treatment setting.

Outpatient vs Inpatient Management

Outpatient Management Considerations

  • Majority of patients can be treated as outpatients unless:

    • History of Delirium Tremens (DTs) or severe withdrawal seizures.

    • Cannot follow medication instructions or has significant alcohol dependence.

    • Serious psychiatric conditions (e.g., exacerbated schizophrenia) requiring higher care.

    • Pregnant women typically need inpatient support.

    • Severe withdrawal symptoms or social isolation can also warrant inpatient care.

Treatment Options for Mild to Moderate Withdrawal in Outpatient Settings

  • Medications:

    • Benzodiazepines: First-line treatment for moderate to severe withdrawal.

    • Gabapentin: Alternative for mild withdrawal and noted for its safety and efficacy; showed effectiveness in outpatient settings.

    • Carbamazepine: Less frequently used, suggested for mild symptomatic management.

  • Important to monitor patients, rely on check-ins or use a patient portal for follow-ups.

Long-term Management of AUD Pharmacotherapy

FDA-approved Medications

  • Naltrexone:

    • Opioid antagonist, effective in reducing cravings and preventing relapse.

    • Number needed to treat (NNT) to prevent a return to any drinking: approximately 20.

    • Careful monitoring required due to potential liver implications; baseline and periodic LFTs advised.

    • Dosage: typically, 50 mg orally per day with an initial lower dose for tolerance.

    • Extended-release injectable form available (Vivitrol).

    • Works effectively even for patients actively drinking but best initiated when abstinent.

  • Acamprosate:

    • Works on GABA and glutamate neurotransmitters, requiring abstinence for maximum effectiveness.

    • Involves pill burden (two tablets three times daily).

    • Noted for its utility in helping maintain sobriety after detoxification.

  • Disulfiram:

    • Acts as a deterrent; causes severe sickness when alcohol is consumed.

    • Dosage: typically, 500 mg for a week, then maintenance dose.

Off-label Medications

  • Gabapentin:

    • Used for withdrawal management, anxiety, and as an adjunctive treatment in AUD.

    • Studies showed success in reducing heavy drinking days; NNT around 5-6 for effectiveness.

  • Topiramate:

    • Known for mood stabilization and weight loss, recommended for patients with mood disorders or seeking weight management.

  • GLP-1 Agonists:

    • Emerging evidence for efficacy in treating AUD; still in exploratory stages.

Monitoring and Evaluation

Ethyl Glucuronide (ETG) Testing

  • Biomarker for alcohol consumption providing a wider detection window than blood tests; can identify consumption days after last use.

  • Useful in verifying abstinence or documenting alcohol use in treatment settings.

Case Study

Jackie D.

  • 43-year-old female with hypertension, anxiety, and fibromyalgia inquiring about alcohol reduction strategies.

  • Discussed alcohol consumption (approximately one bottle of wine daily).

  • Screened with CIWA, demonstrating mild withdrawal.

Management Decisions

  • Discuss whether inpatient detox is necessary based on patient's health history.

  • Outpatient detox using gabapentin employed successfully.

  • Recommendation of naltrexone for maintaining sobriety, while addressing any mental health concerns and potentially using counseling options.

Conclusion

  • Emphasized the treatable nature of AUD, the efficacy of medications, importance of ongoing monitoring, and supportive counseling in recovery processes.

  • Questions invited regarding any specifics or uncertainties within the educational presentation.